UK Users

Access Prodigy topics and clinical content at the NICE website.

Visit the NICE website

Free Trial

To arrange a free trial of the Prodigy application, get in touch.

Contact us to arrange a trial

International Users

The Prodigy application is available on a subscription basis.

Subscription types

Sample Topic: Asthma

Asthma : Last revised in December 2013


New safety alerts

In September 2010, the Medicines and Healthcare products Regulatory Agency (MHRA) issued advice to prescribers that the benefits of using long-acting beta2 agonists (in conjunction with inhaled corticosteroids) in children outweigh any apparent risks. However, prescribers are advised that a daily dose of 24 micrograms formoterol should be sufficient for most children, particularly younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.

  • Reference: MHRA (2010) Long-acting β2-agonists: reminder for use in children and adults. Drug Safety Update 4(2), H2. [Free Full-text]

On 31 March 2009 all stock of NebuChamber® spacer devices (for use with Pulmicort inhalers®) were recalled by AstraZeneca because of reports that the mouthpiece could be attached the wrong way. This is clinically significant because the mouthpiece contains a one-way valve. Patients should be reminded that the frosted end of the mouthpiece must be attached to the spacer.

  • Reference: MHRA (2009) Class 2 Drug Alert (action with 48 hours): AstraZeneca UK Ltd – NebuChamber Device (Inhalation Aid) – EL(09)A/09. Medicines and Healthcare products Regulatory Agency. www.mhra.gov.uk [Free Full-text]